Advance Disease-Modifying Targets, Revolutionize BBB Delivery & Collaborate with Global Partners to Power the Next Frontier of Neuroscience Therapeutics in Korea
Korea is rapidly emerging as a global hub for CNS innovation, with advances spanning diverse modalities, BBB shuttling technologies and differentiated targets beyond Aβ and tau. As a result, pharma and venture interest has surged, with 2026 already witnessing major deals such as Fosun & AriBio, Insilico & SK Biopharmaceuticals and J&J & Prazer Therapeutics, highlighting the significant untapped potential to translate early-stage Korean assets into clinically successful, disease-modifying CNS therapies.
Capitalizing on this skyrocketing investment and innovation momentum, the World CNS Summit South Korea will bring together Korean pioneers like ABL Bio, AriBio and ADEL, alongside international powerhouses including Eli Lilly, Lundbeck, JCR Pharmaceuticals and Novartis to exchange ideas and foster the collaborations needed to drive a new wave of disease-modifying neuroscience therapies.
What Makes This Event Unique?
Korea’s First Industry-led Forum Dedicated to Neuroscience Drug Development:
100% Industry-Based Speaker Faculty
Full Focus On CNS, With Insights Spanning AD, PD, ALS, Epilepsy, Depression, & More
Global Pharma Representation, Attracting R&D & S&E Heads from Asia, US & Europe
Intimate Setting Built for Targeted Networking & Meaningful Collaboration
Attending Companies Include
참석 기업에는 다음이 포함됩니다
Explore Related Events
관련 행사 둘러보기
Explore the Agenda
Hear the latest CNS innovations taking place within South Korea while hearing from global experts.
Partner With Us
Position yourself alongside other leading solution providers to ensure your company is the go-to service providers for Korean neuroscience drug developers.
Join Biopharma Experts
Be part of the hottest conversations with like-minded neuroscientists, C-level executives, heads, VPs, and more across discovery, translational and clinical development.